One weeks treatment with the long acting GLP-1 derivative, NN2211, markedsly increases 24-h glycaemia, reduces endogenous glucose release and improves alfa- and beta-cell function in type 2 diabetes patients

Kirstine Bruun Degn, C.B. Juhl, J. Sturis, B. Jakobsen, V. Chandramouli, Jørgen Rungby, B.R. Landau, Schmitz O.

OriginalsprogEngelsk
TidsskriftDiabetes
Vol/bind53
Sider (fra-til)1187-1194
Antal sider8
ISSN0012-1797
StatusUdgivet - 2004

Citationsformater